Physician profile
David Wang
NPI 1972063709
$2,181.16
in general payments reported to CMS, 2019-2025
21 companies · $271 in 2025
The $271 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $320 · 2022: $505 · 2023: $347 · 2024: $739 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,356.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $348.07 | 2022-2025 | Vyvgart |
| Ucb, INC. | $318.08 | 2023-2024 | Rystiggo, Briviact, Zilbrysq |
| Alexion Pharmaceuticals, INC. | $284.08 | 2021-2024 | Ultomiris |
| Emd Serono, INC. | $196.21 | 2021-2023 | Mavenclad |
| Astrazeneca Pharmaceuticals LP | $190.95 | 2021-2024 | Wainua, Andexxa |
| Genzyme Corporation | $133.84 | 2021-2022 | |
| Genentech USA, INC. | $101.58 | 2022-2025 | Enspryng, Ocrevus, Evrysdi |
| Biohaven Pharmaceutical Holding Company LTD. | $100.77 | 2022 | |
| Averitas Pharma INC. | $77.61 | 2023-2024 | Qutenza |
| Pfizer INC. | $70.85 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $69.84 | 2022-2024 | Hyqvia |
| Acadia Pharmaceuticals INC | $49.72 | 2025 | Nuplazid |
| Biohaven Pharmaceuticals, INC. | $45.97 | 2021 | |
| Jazz Pharmaceuticals INC. | $36.73 | 2024 | |
| Horizon Therapeutics Plc | $36.15 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $31.22 | 2022-2025 | Vumerity |
| Abbvie INC. | $19.96 | 2024 | |
| Amylyx Pharmaceuticals, INC. | $19.30 | 2024 | Relyvrio |
| Lilly USA, LLC | $18.12 | 2024 | Amyvid |
| Celgene Corporation | $16.60 | 2021 | |
| Grifols USA, LLC | $15.51 | 2024 | Gamunex-C |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.